Nuveen Asset Management LLC Has $6.95 Million Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Nuveen Asset Management LLC reduced its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 10.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 125,539 shares of the company's stock after selling 15,186 shares during the period. Nuveen Asset Management LLC owned about 0.33% of Tarsus Pharmaceuticals worth $6,951,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the company. Numerai GP LLC bought a new stake in Tarsus Pharmaceuticals in the fourth quarter valued at approximately $1,034,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $410,000. Millennium Management LLC increased its holdings in shares of Tarsus Pharmaceuticals by 189.4% during the 4th quarter. Millennium Management LLC now owns 644,010 shares of the company's stock worth $35,659,000 after acquiring an additional 421,495 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Tarsus Pharmaceuticals by 3.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,926 shares of the company's stock valued at $1,159,000 after acquiring an additional 724 shares during the period. Finally, Janus Henderson Group PLC lifted its holdings in Tarsus Pharmaceuticals by 47.2% during the 4th quarter. Janus Henderson Group PLC now owns 12,482 shares of the company's stock valued at $691,000 after purchasing an additional 4,000 shares during the last quarter. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Stock Performance

Tarsus Pharmaceuticals stock traded up $0.06 during midday trading on Tuesday, hitting $43.91. The company's stock had a trading volume of 261,524 shares, compared to its average volume of 701,228. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The company has a market cap of $1.84 billion, a price-to-earnings ratio of -11.52 and a beta of 0.94. Tarsus Pharmaceuticals, Inc. has a 1-year low of $20.08 and a 1-year high of $57.28. The company has a 50-day moving average price of $46.65 and a two-hundred day moving average price of $48.91.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The company had revenue of $78.34 million for the quarter, compared to analysts' expectations of $72.50 million. As a group, sell-side analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Insiders Place Their Bets

In other Tarsus Pharmaceuticals news, General Counsel Bryan Wahl sold 3,084 shares of the stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $50.11, for a total transaction of $154,539.24. Following the sale, the general counsel now directly owns 51,712 shares in the company, valued at $2,591,288.32. This represents a 5.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Dianne C. Whitfield sold 2,137 shares of the firm's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $50.11, for a total transaction of $107,085.07. Following the completion of the transaction, the insider now directly owns 46,355 shares in the company, valued at approximately $2,322,849.05. This represents a 4.41% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 32,542 shares of company stock worth $1,581,173 in the last 90 days. Company insiders own 8.25% of the company's stock.

Analyst Ratings Changes

TARS has been the topic of several research reports. Wall Street Zen downgraded shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. The Goldman Sachs Group upped their price target on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research note on Monday, May 5th. Oppenheimer started coverage on shares of Tarsus Pharmaceuticals in a report on Monday. They issued an "outperform" rating and a $75.00 price target on the stock. Barclays reduced their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Finally, HC Wainwright upgraded Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 target price on the stock in a research note on Tuesday, May 27th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $66.67.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.